SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sailana Inu, the sister of legendary Saitama Inu, is bringing back the Wolfpack and OG community vibes that previously sent Saitama to a $7 billion marketcap in 2021. The power of community mixed with great leadership is what will take this project to great heights. Join the movement, join the pack, become apart of the Sailana Army . Together, we will create something that will go down in history, and something that will be talked about years from now.

Sailana Inu

Sailana Inu is trending amid strong community enthusiasm for its new WolfSWAP, a cross-chain aggregator offering utility and fee-sharing across over 20 networks. The "Wolfpack" believes this focus on decentralization and innovation, with a significant flagship utility planned for 2026, sets SAILANA apart as a memecoin building long-term value and garnering "early $SHIB vibes" from believers.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano is at the center of a highly polarized community discussion, with significant frustration over its sustained market performance leading to strong FUD and accusations against its founder. Conversely, its native meme coin ecosystem, featuring projects like $COCK and $NIGHT, continues to launch new dApps and establish partnerships, creating a counter-narrative of ecosystem growth. The cryptocurrency is also being actively compared to newer Layer 1 infrastructures like Keeta ($KTA), which proponents highlight for its high-throughput and compliance-focused design for institutional finance.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network (ZBCN) is actively trending as the community highlights its recent ISO 20022 compliance and expanding partnerships with key financial institutions like Nacha and NatPay, positioning it for future utility in real-time payments. While discussions include anticipation for its Super App and the distinction of its Coinbase tradability, many investors view current price levels as a significant accumulation phase for a potentially transformative long-term crypto asset.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

ARS Pharmaceuticals Inc

ARS Pharmaceuticals (SPRY) is trending due to accelerating adoption of its Neffy nasal spray, supported by robust revenue growth and expanding global approvals across Europe and Asia. Community discussion highlights both significant short squeeze potential and intense debate over Neffy's market share against competitors, including a citizen petition filed by SPRY. The company's non-dilutive funding and pursuit of new indications like hives treatment further underscore its strategy to disrupt the allergy care market.

Snek is a cultural movement and leading currency for meme creators worldwide.

SNEK

SNEK is currently trending due to its growing utility as a liquidity bridge within the Cardano ecosystem, facilitating capital movement between major assets and stablecoins. The community is buzzing about its strong partnership with $COCK for real-world asset integration with "Snek Energy" drinks and recent major exchange listings, highlighting its sustained relevance and innovative approach beyond typical meme coin speculation.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending following a significant strategic investment from a major AI chipmaker and its multi-billion dollar commitment to expand AI-integrated network technologies in the US. The community is actively debating whether these strong fundamental catalysts, coupled with positive institutional interest and analyst upgrades, will overcome historical price volatility and perceived market suppression.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp ($OMER) is trending following the FDA approval of YARTEMLEA, its first-and-only therapy for transplant-associated thrombotic microangiopathy (TA-TMA), with a U.S. launch slated for early January. Investors are highly optimistic about the drug's market monopoly and pricing power, alongside the company's bolstered financial position from a major partnership. Community discussions are vibrant, with many anticipating further positive updates like potential European collaborations during the upcoming conference call, while others remain cautious of short-term volatility.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending following strong quarterly earnings, numerous analyst upgrades and raised price targets, and a substantial share repurchase authorization, signaling positive momentum for its core business. However, significant community discussion revolves around persistent platform outages and trading restrictions, leading some to critique the company's technology compared to agile competitors, even as client assets continue to grow substantially.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

Midnight ($NIGHT) is trending following recent major exchange listings, a significant token airdrop, and a substantial surge in trading volume. Community discussions center on its 

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies is trending after its QPerfect division launched a GPU-accelerated quantum emulator with NVIDIA CUDA-Q compatibility, significantly advancing its technological capabilities. This integration has sparked community excitement, positioning BTQ as a critical player in developing post-quantum cryptography for digital assets and financial systems against emerging quantum threats. While enthusiasm builds for potential widespread adoption, the market remains keenly focused on future revenue generation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced that...

PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial

PLSE has secured FDA IDE approval to launch its nPulse AF ablation study.

Pulse Biosciences (NASDAQ:PLSE) Trading Up 5% - Here's What Happened

Pulse Biosciences (NASDAQ:PLSE) Trading 5% Higher - Time to Buy...

PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor

Pulse Biosciences partners with MD Anderson to study its nPulse technology for treating benign and malignant thyroid tumors upon receiving FDA approval for a first-in-human trial.

Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse Technology

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company or Pulse Biosciences), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or...

Pulse Biosciences (NASDAQ:PLSE) Hits New 12-Month Low - Here's What Happened

Pulse Biosciences (NASDAQ:PLSE) Reaches New 12-Month Low - Time to Sell...

Pulse Biosciences is Now Oversold (PLSE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...

Pulse Biosciences (NASDAQ:PLSE) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts...

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced plans...

Pulse Biosciences, Inc (PLSE) Reports Q3 Loss, Lags Revenue Estimates

Pulse Biosciences (PLSE) delivered earnings and revenue surprises of +6.45% and -82.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

Current Price	$14.40
Prev Close	$14.86
Open	$14.80
Dividend Yield	0.00%
50-Day Moving Average	$15.03
Beta	1.35
Avg. Volume	177,411.79
PE Ratio	-12.68

52-Week High	$25.00
52-Week Low	$12.56
Market Capitalization	$975.85M
EPS (Annual)	-$0.9176
Price to Book	10.52
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

PLSE
Pulse Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PLSE News

PLSEPulse Biosciences Inc